Reliability of the histopathologic diagnosis of keratinocyte carcinomas

J Am Acad Dermatol. 2007 Aug;57(2):279-84. doi: 10.1016/j.jaad.2007.03.021. Epub 2007 May 7.

Abstract

Objective: We sought to determine the interobserver reliability of the histopathologic diagnosis of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) (keratinocyte carcinomas) in the setting of a Department of Veteran Affairs multicenter chemoprevention study.

Methods: Interobserver concordance was assessed by blinded review of histopathologic slides by study dermatopathologists.

Results: Overall interobserver agreement between the two dermatopathogists was kappa = 0.69 (95% confidence interval [CI] 0.67-0.69). The dermatopathologists' interobserver agreement was highest for basal cell carcinoma at kappa = 0.88 (95% CI 0.84-0.91) and for a diagnostic category in the SCC-actinic keratosis spectrum at kappa = 0.80 (95% CI 0.73-0.86). The largest disagreements between the two reference dermatopathologists were regarding the categories of invasive SCC at kappa = 0.62 (95% CI 0.52-0.72), SCC in situ at kappa = 0.42 (95% CI 0.29-0.56), and actinic keratosis at kappa = 0.51 (95% CI 0.40-0.62). Agreement between the local pathologists and central reference dermatopathologists were similar to the agreement between the central dermatopathologists. The morphea subtype of basal cell carcinoma was the only reliably diagnosed subtype (kappa = 0.79, 95% CI 0.51-1.00), and tumor depth was reliably measured.

Limitations: A limitation of this study was the use of only two reference dermatopathologists.

Conclusion: Because of the impact on physician decision making and patient care, researchers and clinicians need to be aware of reliability of histopathology results, particularly pertaining to the SCC and actinic keratosis spectrum.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Biopsy / standards
  • Carcinoma, Basal Cell / pathology*
  • Carcinoma, Squamous Cell / pathology*
  • Ear Neoplasms / pathology*
  • Facial Neoplasms / pathology*
  • Humans
  • Keratinocytes / pathology
  • Keratolytic Agents / therapeutic use
  • Keratosis / pathology
  • Keratosis / prevention & control
  • Neoplasm Invasiveness / pathology
  • Observer Variation
  • Photosensitivity Disorders / pathology
  • Photosensitivity Disorders / prevention & control
  • Reproducibility of Results
  • Tretinoin / therapeutic use

Substances

  • Keratolytic Agents
  • Tretinoin